Johnson & Johnson operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Johnson & Johnson with three other
major healthcare and pharmaceutical companies:
Bristol-Myers Squibb Company
sales of $42.52 billion
of which 28%
was Prioritized Brands-Revlimid),
Baxter International Inc.
of which 52%
was Americas), and
based in SWITZERLAND
(46.58 billion Swiss Francs [US$50.41 billion]
of which 78%
was Innovative Medicines).
During the second
quarter of 2021, sales at Johnson & Johnson totalled
an increase of 27.1%
from the $18.34 billion in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Johnson & Johnson in the previous 35 quarters.
During the first two
quarters of 2021, sales totalled $45.63 billion, which is
than through the first two quarters of 2020.
During the year ended December of 2020, sales at
Johnson & Johnson were $82.58 billion.
a very small
increase of 0.6%
versus 2019, when the company's sales were $82.06 billion.
This was the fifth consecutive year of sales increases at Johnson & Johnson
(and since 2015, sales have increased a total of 18%).
Sales of Pharmaceutical saw an increase
that was more than double the company's growth rate: sales were up
8.0% in 2020, from
$42.20 billion to $45.57 billion.
Johnson & Johnson also saw significant increases in sales in
Consumer (up 1.1% to $14.05 billion)
Not all segments of Johnson & Johnson experienced an increase in sales in 2020:
sales of Medical Devices fell 11.6% to $22.96 billion.